Rachel Culp-Hill, Ph.D.
About Rachel Culp-Hill, Ph.D.
Rachel Culp-Hill, Ph.D., is a Mass Spectrometry Scientist with extensive expertise in metabolomics and over a decade of experience in mass spectrometry, focusing on metabolic alterations in various diseases.
Rachel Culp-Hill, Ph.D. - Mass Spectrometry Scientist
Rachel Culp-Hill, Ph.D., is a seasoned mass spectrometry scientist with a specialization in metabolomics. With over a decade of experience in mass spectrometry, she has carved a niche in the exploration of metabolic alterations in various disease states. Her expertise centers around understanding complex metabolic processes, particularly in the context of serious illnesses such as acute myeloid leukemia, Down Syndrome, sickle cell disease, breast cancer, and hemorrhagic shock.
Rachel Culp-Hill, Ph.D. - Education and Academic Background
Rachel Culp-Hill holds a Ph.D. in Biochemistry from the University of Colorado Anschutz Medical Campus. Prior to earning her doctorate, she obtained a Master of Science degree in Microbiology from the University of Florida. She also completed her Bachelor of Science in Biochemistry and Molecular Biology from Michigan State University. This robust educational foundation has underpinned her advances and contributions in the fields of biochemistry and mass spectrometry.
Rachel Culp-Hill's Research Focus and Publications
Rachel Culp-Hill's research has primarily focused on studying metabolic alterations associated with various diseases. She has made significant contributions to understanding the metabolome of acute myeloid leukemia stem cells and other cancers. Her groundbreaking work has been featured in prominent scientific journals such as Nature Medicine, Nature Cancer, Cell, Cancer Cell, Cell Stem Cell, and Blood. Her research aims to elucidate complex metabolic pathways and offers insights valuable for the development of new diagnostics and treatments.
Rachel Culp-Hill's Projects: Diagnostic and GlycoLocate™ Platform
Currently, Rachel Culp-Hill is dedicating her expertise to validate a diagnostic test for ovarian cancer. Additionally, she is expanding the GlycoLocate™ platform to detect additional cancer targets. These projects underscore her commitment to leveraging mass spectrometry and metabolomics for improving cancer diagnostics and broadening the scope of detectable cancer markers, ultimately aiming to enhance patient outcomes through more precise and early detection methods.